Uptake of inflammatory cell marker [11C]PK11195 into mouse atherosclerotic plaques

  • Iina Laitinen
  • Päivi Marjamäki
  • Kjell Någren
  • V. Jukka O. Laine
  • Ian Wilson
  • Pia Leppänen
  • Seppo Ylä-Herttuala
  • Anne Roivainen
  • Juhani Knuuti
Original Article



The ligand [11C]PK11195 binds with high affinity and selectivity to peripheral benzodiazepine receptor, expressed in high amounts in macrophages. In humans, [11C]PK11195 has been used successfully for the in vivo imaging of inflammatory processes of brain tissue. The purpose of this study was to explore the feasibility of [11C]PK11195 in imaging inflammation in the atherosclerotic plaques.


The presence of PK11195 binding sites in the atherosclerotic plaques was verified by examining the in vitro binding of [3H]PK11195 onto mouse aortic sections. Uptake of intravenously administered [11C]PK11195 was studied ex vivo in excised tissue samples and aortic sections of a LDLR/ApoB48 atherosclerotic mice. Accumulation of the tracer was compared between the atherosclerotic plaques and non-atherosclerotic arterial sites by autoradiography and histological analyses.


The [3H]PK11195 was found to bind to both the atherosclerotic plaques and the healthy wall. The autoradiography analysis revealed that the uptake of [11C]PK11195 to inflamed regions in plaques was more prominent (p = 0.011) than to non-inflamed plaque regions, but overall it was not higher than the uptake to the healthy vessel wall. Also, the accumulation of 11C radioactivity into the aorta of the atherosclerotic mice was not increased compared to the healthy control mice.


Our results indicate that the uptake of [11C]PK11195 is higher in inflamed atherosclerotic plaques containing a large number of inflammatory cells than in the non-inflamed plaques. However, the tracer uptake to other structures of the artery wall was also prominent and may limit the use of [11C]PK11195 in clinical imaging of atherosclerotic plaques.


Atherosclerosis Autoradiography Biodistribution Cardiology molecular imaging 11C-PK11195 


  1. 1.
    Jander S, Sitzer M, Schumann R, Schroeter M, Siebler M, Steinmetz H, et al. Inflammation in high-grade carotid stenosis: a possible role for macrophages and T cells in plaque destabilization. Stroke 1998;29:1625–30.PubMedGoogle Scholar
  2. 2.
    Moreno PR, Bernardi VH, Lopez-Cuellar J, Murcia AM, Palacios IF, Gold HK, et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 1996;94:3090–7.PubMedGoogle Scholar
  3. 3.
    Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 2003;108:1664–72.PubMedCrossRefGoogle Scholar
  4. 4.
    Laitinen I, Marjamäki P, Haaparanta M, Savisto N, Laine VJ, Soini SL, et al. Non-specific binding of [18F]FDG to calcifications in atherosclerotic plaques: experimental study of mouse and human arteries. Eur J Nucl Med Mol Imaging 2006;33:1461–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Ogawa M, Ishino S, Mukai T, Asano D, Teramoto N, Watabe H, et al. [18F]-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. J Nucl Med 2004;45:1245–50.PubMedGoogle Scholar
  6. 6.
    Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002;105:2708–11.PubMedCrossRefGoogle Scholar
  7. 7.
    Tawakol A, Migrino RQ, Hoffmann U, Abbara S, Houser S, Gewirtz H, et al. Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. J Nucl Cardiol 2005;12:294–301.PubMedCrossRefGoogle Scholar
  8. 8.
    Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapere JJ, Lindemann P, et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006;27:402–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Le Fur G, Guilloux F, Rufat P, Benavides J, Uzan A, Renault C, et al. Peripheral benzodiazepine binding sites: effect of PK 11195, 1-(2-chlorophenyl)-N-methyl-(1-methylpropyl)-3 isoquinolinecarboxamide. II. In vivo studies. Life Sci 1983;32:1849–56.PubMedCrossRefGoogle Scholar
  10. 10.
    Canat X, Carayon P, Bouaboula M, Cahard D, Shire D, Roque C, et al. Distribution profile and properties of peripheral-type benzodiazepine receptors on human hemopoietic cells. Life Sci 1993;52:107–18.PubMedCrossRefGoogle Scholar
  11. 11.
    Zavala F, Haumont J, Lenfant M. Interaction of benzodiazepines with mouse macrophages. Eur J Pharmacol 1984;106:561–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Anholt RR, De Souza EB, Oster-Granite ML, Snyder SH. Peripheral-type benzodiazepine receptors: autoradiographic localization in whole-body sections of neonatal rats. J Pharmacol Exp Ther 1985;233:517–26.PubMedGoogle Scholar
  13. 13.
    Parola AL, Yamamura HI, Laird HE III. Peripheral-type benzodiazepine receptors. Life Sci 1993;52:1329–42.PubMedCrossRefGoogle Scholar
  14. 14.
    Veenman L, Gavish M. The peripheral-type benzodiazepine receptor and the cardiovascular system. Implications for drug development. Pharmacol Ther 2006;110:503–24.PubMedCrossRefGoogle Scholar
  15. 15.
    Hardwick MJ, Chen MK, Baidoo K, Pomper MG, Guilarte TR. In vivo imaging of peripheral benzodiazepine receptors in mouse lungs: a biomarker of inflammation. Mol Imaging 2005;4:432–8.PubMedGoogle Scholar
  16. 16.
    Jones HA, Valind SO, Clark IC, Bolden GE, Krausz T, Schofield JB, et al. Kinetics of lung macrophages monitored in vivo following particulate challenge in rabbits. Toxicol Appl Pharmacol 2002;183:46–54.PubMedCrossRefGoogle Scholar
  17. 17.
    Jones HA, Marino PS, Shakur BH, Morrell NW. In vivo assessment of lung inflammatory cell activity in patients with COPD and asthma. Eur Respir J 2003;21:567–73.PubMedCrossRefGoogle Scholar
  18. 18.
    Heinonen SE, Leppänen P, Kholova I, Lumivuori H, Häkkinen SK, Bosch F, et al. Increased atherosclerotic lesion calcification in a novel mouse model combining insulin resistance, hyperglycemia, and hypercholesterolemia. Circ Res 2007;101:1058–67.PubMedCrossRefGoogle Scholar
  19. 19.
    Leppänen P, Koota S, Kholova I, Koponen J, Fieber C, Eriksson U, et al. Gene transfers of vascular endothelial growth factor-A, vascular endothelial growth factor-B, vascular endothelial growth factor-C, and vascular endothelial growth factor-D have no effects on atherosclerosis in hypercholesterolemic low-density lipoprotein-receptor/apolipoprotein B48-deficient mice. Circulation 2005;112:1347–52.PubMedCrossRefGoogle Scholar
  20. 20.
    Veniant MM, Pierotti V, Newland D, Cham CM, Sanan DA, Walzem RL, et al. Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. J Clin Invest 1997;100:180–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Debruyne JC, Versijpt J, Van Laere KJ, De Vos F, Keppens J, Strijckmans K, et al. PET visualization of microglia in multiple sclerosis patients using [11C]PK11195. Eur J Neurol 2003;10:257–64.PubMedCrossRefGoogle Scholar
  22. 22.
    Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr., et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995;92:1355–74.PubMedGoogle Scholar
  23. 23.
    McEnery MW, Snowman AM, Trifiletti RR, Snyder SH. Isolation of the mitochondrial benzodiazepine receptor: association with the voltage-dependent anion channel and the adenine nucleotide carrier. Proc Natl Acad Sci U S A 1992;89:3170–4.PubMedCrossRefGoogle Scholar
  24. 24.
    Zavala F, Lenfant M. Benzodiazepines and PK 11195 exert immunomodulating activities by binding on a specific receptor on macrophages. Ann N Y Acad Sci 1987;496:240–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Casellas P, Galiegue S, Basile AS. Peripheral benzodiazepine receptors and mitochondrial function. Neurochem Int 2002;40:475–86.PubMedCrossRefGoogle Scholar
  26. 26.
    Branley HM, du Bois RM, Wells AU, Jones HA. Peripheral-type benzodiazepine receptors in bronchoalveolar lavage cells of patients with interstitial lung disease. Nucl Med Biol 2007;34:553–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Bazzichi L, Betti L, Giannaccini G, Rossi A, Lucacchini A. Peripheral-type benzodiazepine receptors in human mononuclear cells of patients affected by osteoarthritis, rheumatoid arthritis or psoriasic arthritis. Clin Biochem 2003;36:57–60.PubMedCrossRefGoogle Scholar
  28. 28.
    De Vos F, Dumont F, Santens P, Slegers G, Dierckx R, De Reuck J. High-performance liquid chromatographic determination of [11C]1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline carboxamide in mouse plasma and tissue and in human plasma. J Chromatogr B Biomed Sci Appl 1999;736:61–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Virsu P, Laitinen I, Pöyhönen T, Någren K, Roivainen A. In vivo biodistribution, biokinetics and blood metabolism of [11C]PK11195 in rats—a PET tracer for peripheral benzodiatsepine receptor. Eur J Nucl Med Mol Imaging 2005;32:S266.Google Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Iina Laitinen
    • 1
  • Päivi Marjamäki
    • 1
  • Kjell Någren
    • 1
  • V. Jukka O. Laine
    • 2
  • Ian Wilson
    • 3
  • Pia Leppänen
    • 4
  • Seppo Ylä-Herttuala
    • 4
  • Anne Roivainen
    • 1
  • Juhani Knuuti
    • 1
  1. 1.Turku PET CentreUniversity of TurkuTurkuFinland
  2. 2.Department of PathologyTurku University HospitalTurkuFinland
  3. 3.Medical DiagnosticsGE Healthcare BiosciencesLondonUK
  4. 4.A.I. Virtanen InstituteUniversity of KuopioKuopioFinland

Personalised recommendations